Grant of Share Options - replacement
The following amendment has been made to the ' Grant of Share Options' announcement released on
The sentence "All the Share Options granted one twelfth of the Share Options vest 3 months from the date of grant with one twelfth vesting quarterly after that, subject to the individuals remaining employed by the Company as Non-Executive Directors" has been removed and replaced with "The share option grant would vest 100% in 12 months from date of grant".
All other details remain unchanged.
The full amended text is shown below.
("Renalytix" or the "Company")
Grant of Share Options
|
|
Position |
Options granted |
|
|
|
|
|
|
Non-Executive Chairman |
95,000 |
|
|
Non-Executive Director |
95,000 |
|
|
Non-Executive Director |
95,000 |
|
|
Non-Executive Director |
95,000 |
The Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of
The share option grant would vest 100% in 12 months from date of grant.
The issue of the Share Options are deemed to be related party transactions pursuant to AIM Rule 13 of the AIM Rules for Companies. The Company's directors (excluding those who are being awarded the Share Options) consider, having consulted with the Nominated Adviser,
For further information, please contact:
|
|
|
|
|
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
|
|
|
|
|
|
|
Tel: 020 7597 4000 |
|
|
|
|
|
|
|
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
|
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
|
|
|
|
|
|
|
|
Tel: 415-389-6400 or investors@renalytix.com |
About Renalytix
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
|
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Non-Executive Chairman |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
|
|
|||
|
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of |
|||
|
|
|
||||
|
Identification code |
GB00BYWL4Y04 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of options over shares |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
|
95,000 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
95,000 |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
|
|||
|
f)
|
Place of the transaction
|
Outside of trading venue - off market |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
|
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Non-Executive Director |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
|
|
|||
|
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of |
|||
|
|
|
||||
|
Identification code |
GB00BYWL4Y04 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of options over shares |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
|
95,000 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
95,000 |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
|
|||
|
f)
|
Place of the transaction
|
Outside of trading venue - off market |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
|
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Non-Executive Director |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
|
|
|||
|
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of |
|||
|
|
|
||||
|
Identification code |
GB00BYWL4Y04 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of options over shares |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
|
95,000 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
95,000 |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
|
|||
|
f)
|
Place of the transaction
|
Outside of trading venue - off market |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
|
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Non-Executive Director |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
|
|
|||
|
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of |
|||
|
|
|
||||
|
Identification code |
GB00BYWL4Y04 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of options over shares |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
|
95,000 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
95,000 |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
|
|||
|
f)
|
Place of the transaction
|
Outside of trading venue - off market |
|||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the